Miktosan (Tamsulosin Hydrochloride)

Miktosan is an alpha‑1 blocker indicated for conditions affecting the prostate and urinary flow.

• Benign prostatic hyperplasia (BPH): improves urinary flow and reduces bladder outlet obstruction.
• Lower urinary tract symptoms associated with BPH: alleviates urgency, frequency, nocturia and weak stream.
• Prostatic enlargement: relaxes smooth muscle tone in the prostate, bladder neck and urethra to ease voiding.

• Tamsulosin Hydrochloride selectively blocks alpha‑1 adrenergic receptors located in the prostate, bladder neck and urethra. This inhibition reduces smooth‑muscle tone in these tissues, leading to decreased resistance to urinary flow and relief of obstruction caused by benign prostatic hyperplasia.

Miktosan may cause a range of adverse reactions.

Common Side Effects

• Dizziness: feeling light‑headed, especially on standing.
• Headache: mild to moderate intensity.
• Abnormal ejaculation: reduced volume or retrograde flow.
• Nasal congestion: stuffy or runny nose.
• Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Priapism: prolonged, painful erection.
• Allergic reactions: rash, itching, swelling or anaphylaxis.
• Intraoperative floppy iris syndrome (IFIS): potential complication during eye surgery.

Before initiating therapy, consider the following precautions.

• Blood pressure monitoring: watch for orthostatic hypotension, especially after the first dose.
• Liver disease: use with caution in patients with moderate to severe hepatic impairment.
• Concomitant alpha‑1 blockers: avoid additive hypotensive effects.
• Eye surgery: inform surgeons of tamsulosin use due to risk of IFIS.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and light.

Tamsulosin can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase tamsulosin plasma levels.
• Other alpha‑1 blockers (e.g., prazosin, doxazosin): additive hypotensive effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce tamsulosin efficacy.
• Diuretics: may enhance orthostatic hypotension, requiring careful blood pressure checks.
• Warfarin: may increase INR; monitor coagulation parameters regularly.